Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (236)	4/30/2002 8:01:31 PM
From: Michael Young	Read Replies (1) \| Respond to of 508

I have no idea where the stock goes in the near term. My guess is it stays in the $20-40 range before the data is released. I also expect the usual biotech shorts to start sniffing around soon. MIKE

To: IRWIN JAMES FRANKEL who wrote (236)	5/8/2002 8:14:08 AM
From: rkrw	Read Replies (1) \| Respond to of 508

This is a big loss for itmn. I bet he resurfaces as a ceo somewhere soon. Wednesday May 8, 7:30 am Eastern Time Press Release SOURCE: InterMune, Inc. InterMune Announces Senior Management Changes BRISBANE, Calif., May 8 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN - news) announced today that Timothy P. Lynch, Chief Financial Officer, is leaving the company to pursue new career opportunities. The company also announced the promotion of Bradley R. Scates, Controller, to the position of Vice President, Finance. Scates will assume Mr. Lynch's duties until a new CFO is named and will report directly to W. Scott Harkonen, M.D., President and Chief Executive Officer of InterMune.